Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: Lancet Rheumatol. 2024 Jan 29;6(3):e168–e177. doi: 10.1016/S2665-9913(23)00320-X

Table 2:

Adverse events in the safety population.

Maintenance (n=50)1, 2 Withdrawal (n=52)1, 2

n (%) Events, n n (%) Events, n
Serious Adverse Events 7 (14·0) 12 5 (9·6) 6
Total Adverse Events 45 (90·0) 189 46 (88·5) 205
  Related to SLE* 25 (50·0) 63 32 (61·5) 79
Adverse Events by Severity
  Grade 1 0 0 1 (1·9) 1
  Grade 2 45 (90·0) 169 45 (86·5) 189
  Grade 3 10 (20·0) 18 11 (21·2) 15
  Grade 4 2 (4·0) 2 0 0
Total Infections 32 (64·0) 63 24 (46·2) 49
Infections by Severity
  Grade 2 30 (60·0) 57 24 (46·2) 48
  Grade 3 4 (8·0) 6 1 (1·9) 1
  Grade 4 0 0 0 0
*

Related includes definitely, probably, or possibly related.

1

Percentages for the number of subjects with AEs/SAEs are based on the number of subjects in the safety population (N).

2

Subjects who experienced one or more adverse events in a category are counted only once.